Avid Bioservices Inc (CDMO)

[biopharm]

Hood winked by a den of thieves. Now will see what evolves from here.

The thieves would be Big Pharma, but speaking of Hood, do you think Dr Leroy E. Hood was interested in Biomarkers based on PS Targeting, and they possibly poached Dr Hyam Levitsky patent partner ...over to Accelerator Life Science Partners? I bet Dr Mohler knows well about PS Targeting

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=5719023

http://www.acceleratorlsp.com/our-team/dr-steven-gillis/
http://www.acceleratorlsp.com/our-team/david-hirsh/
http://www.acceleratorlsp.com/our-team/dr-leroy-hood/
http://www.acceleratorlsp.com/our-team/sundar-kodiyalam/
http://www.acceleratorlsp.com/our-team/thong-q-le/
http://www.acceleratorlsp.com/our-team/joel-s-marcus/
http://www.acceleratorlsp.com/our-team/dr-james-p-sullivan/
http://www.acceleratorlsp.com/our-team/dr-asish-k-xavier/
http://www.acceleratorlsp.com/our-team/dr-tadataka-yamada/

http://www.acceleratorlsp.com/our-team/dr_kendall_mohler/

Dr. Kendall M. Mohler, also known as Ken, Ph.D. is a Chief Development Officer at Accelerator Life Science Partners. He was Senior Vice President of Research at Juno Therapeutics Inc. since May 28, 2015. Dr. Mohler served as the Chief Scientific Officer of Juno Therapeutics Inc. until May 28, 2015. Dr. Mohler joined Juno in October 2013.
...
https://www.bloomberg.com/research/stocks/private/person.asp?personId=1492961&privcapId=252447310

....James P Sullivan from Abbvie in the mix as well....
http://www.acceleratorlsp.com/our-team/

https://www.linkedin.com/in/jim-sullivan-92576411

ENGINEERED CELLS FOR ADOPTIVE CELL THERAPY
Publication number: 20170204372
Abstract: Provided are engineered cells for adoptive therapy, including NK cells and T cells. Also provided are compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some aspects, features of the cells and methods provide specificity and/or efficacy. In some embodiments, the cells contain genetically engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and costimulatory receptors. In some embodiments, the cells include receptors targeting multiple antigens. In some embodiments, the cells include repression of one or more gene product, for example, by disruption of a gene encoding the gene product. In some embodiments, a gene encoding an antigen recognized by the engineered antigen receptor is disrupted, reducing the likelihood of targeting of the engineered cells.
Type: Application
Filed: July 15, 2015
Publication date: July 20, 2017
Applicant: Juno Therapeutics, Inc.
Inventors: Kendall M. MOHLER, Hyam I. LEVITSKY

https://patents.justia.com/inventor/hyam-i-levitsky

________

Now the question is, do shareholders of Peregrine Pharmaceuticals, now being called Avid Bioservices, want to sit back and wait or take further action now because it is obvious that the new BODs want to shut down complete MSK research and NCCN trials and then just let the pipeline bleed

Sanford Markiwitz- Rodeo Therapeutics
https://patents.justia.com/inventor/sanford-d-markowitz